
Table of Contents

■ SECTION I: Fundamentals of US Pharmaceutical and Biologics Regulations

Chapter 1	History of Food, Drug and Cosmetic Laws.....	1
	<i>Updated by Meredith Brown-Tuttle, RAC, FRAPS</i>	
Chapter 2	Overview of Drug, Biologic, Device, Combination Product or Food Regulatory Pathways	13
	<i>Updated by Michael R. Hamrell, PhD, RQAP-GCP, CCRA, FACRP, RAC, FRAPS</i>	
Chapter 3	Clinical Trials: GCPs, Regulations and Compliance for Drugs, Biologics and Medical Devices	45
	<i>Updated by Monique Carter, MS, RAC and Samantha Zappia, MS, RAC</i>	
Chapter 4	Current Good Manufacturing Practices and Quality System Design.....	83
	<i>Updated by Joscelyn Bowersock, MS-RA, and Richard Vincins, CQP, MCQL, CBA, CQA, RAC</i>	
Chapter 5	Prescription Product Drug Submissions	99
	<i>By Shyamala Jayaraman, PhD, Lean Six Sigma Black Belt and Glen D. Park, PharmD, MSJ</i>	
Chapter 6	Postapproval Submissions and Compliance: Prescription Drugs and Biologics.....	121
	<i>Updated by Emily Rapp, RAC and Dar Rosario, MBA, RAC</i>	
Chapter 7	Generic Drug Submissions	141
	<i>Updated by Amrita Ghosh, RAC and Sharry Arora, MPharm</i>	
Chapter 8	Patents and Exclusivity	153
	<i>Updated by Kurt R. Karst, JD</i>	
Chapter 9	Over-the-Counter (Nonprescription) Drug Products	167
	<i>Updated by Valerie Ramsey, DRSc, MS, RAC</i>	
Chapter 10	Prescription Drug Labeling, Advertising and Promotion	177
	<i>Updated by Anu Gaur, PhD, MBA, MSRA, RAC</i>	
Chapter 11	Pharmacovigilance and Risk Management.....	191
	<i>Updated by Stacy Woepfel, MBA and Robert Falcone, PhD</i>	
Chapter 12	Biologics Submissions.....	205
	<i>Updated by Jocelyn Jennings, MS, RAC</i>	

Chapter 13	Biologics Compliance	233
	<i>Updated by Anne Marie Woodland, MS, RAC</i>	
Chapter 14	Biosimilars	245
	<i>Updated by Nathalie Innocent, MS, RAC and Jennifer Wilhelm, MSc, MBA, RAC</i>	
Chapter 15	Biologics Labeling, Advertising and Promotion	267
	<i>By Kathrin Schalper, PhD, RAC</i>	
	Glossary of Terms.....	279
	Index of Laws and Guidances	303
	Index by Subject	307

Figures

Figure 2-1.	Decision Tree for Drug and Device Development and Approval When FDA Premarket Review is Required	21
Figure 2-2.	CTD Organization.....	27
Figure 3-1.	Types of Pharmaceutical and Biologic Clinical Trials and Typical Pathway	54
Figure 3-2.	Types of Medical Device Clinical Trials and Typical Pathway	67
Figure 4-1.	Quality System Documentation Elements	85
Figure 4-2.	Design Control “V” Model Process Flow	86
Figure 5-1.	FDA IND Review Process	105
Figure 5-2.	Diagram of the ICH Common Technical Document (CTD).....	111
Figure 5-3.	Timeline and Product Review Clock.....	114
Figure 6-1.	Summary of Reporting Categories for Postapproval Changes.....	126
Figure 6-2.	Example of a CMC Index	132
Figure 9-1.	Example of an OTC Drug Facts Label	174
Figure 14-1.	Number of Biosimilar INDs Received by CDER by Fiscal Yeara	249
Figure 14-2.	Number of Biosimilar Type 1–4 Meetings Held by CDER by Fiscal Yeara.....	249

Tables

Table 1-1.	Electronic Resources for US Laws and Regulations	3
Table 1-2.	Other Laws, Regulations and Guidelines	10
Table 2-1.	Title 21 CFR Parts	20
Table 2-2.	Key Questions in a Drug Development Program	23
Table 2-3.	IND Safety Reporting Timeframes	29
Table 2-4.	Summary of Device Classification System	36
Table 3-1.	Significant Legislation Relevant to Clinical Trials in the US	48
Table 3-2.	Comparison of 21 CFR and ISO–GCP Requirements for Protocol Deviations in Medical Device Clinical Trials.....	52
Table 3-3.	Comparison of 21 CFR and ISO GCP Requirements for Investigator Responsibilities in Medical Device Clinical Trials.....	73
Table 3-4.	Comparison of 21 CFR and ISO–GCP Requirements for Recordkeeping in Medical Device Clinical Trials.....	74
Table 3-5.	Comparison of 21 CFR and ISO–GCP Requirements for Device Accountability in Medical Device Clinical Trials.....	75

Table 8-1.	180-Day Exclusivity Forfeiture Snapshot.....	161
Table 8-2.	Differences Among Applications Submitted and Approved Under FD&C Act Section 505	162
Table 9-1.	OTC Monograph Therapeutic Category Subtopics Evaluated as Part of the OTC Review Process	170
Table 9-2.	Acne Drug Products: Benzoyl Peroxide.....	171
Table 9-3.	NDA vs. OTC Drug Monograph.....	172
Table 10-1.	PLR Format, Associated Regulations and Guidance Documents	182
Table 10-1.	PLR Format, Associated Regulations and Guidance Documents (cont'd.)	183
Table 11-1.	Safety Reporting Requirements for Drugs/Biologics	200
Table 11-2.	Safety Reporting Requirements for Medical Devices.....	201
Table 12-1.	Key Milestones in the Regulatory Oversight of Biologics	209
Table 12-2.	Applications Regulated by PHS Act	210
Table 12-3.	Applications Regulated by the FD&C Act.....	211
Table 12-4.	Biologics Controlled by CDER and CBER.....	212
Table 12-5.	Submissions With Specific Regulatory Mandated Timelines (e.g., SPAs) or FDA Established Timelines (e.g., Reviews of Proposed Pediatric Study Requests).....	214
Table 12-6.	Safety-Related Submissions	216
Table 12-7.	IND Drug Development Submissions	218
Table 12-7.	IND Drug Development Submissions (cont'd.)	219
Table 12-8.	Other Submission Types.....	220
Table 12-9.	Key CMC Guidance for Biological Product Development	222
Table 12-9.	Key CMC Guidance for Biological Product Development (cont'd.).....	223
Table 12-10.	NDA/BLA Standard and Priority Review Process (PDUFA VI)	226
Table 14-1.	BsUFA Fees Financial Year 2019a.....	248
Table 14-2.	Meetings Between FDA and Biosimilar Biological Product Sponsors	250
Table 14-3.	Comparison of Development Programs Between Chemical Drugs and Biological Products	254
Table 14-4.	FDA-Approved Biosimilars.....	259

■ SECTION II: Fundamentals of Canadian Pharmaceutical and Biologics Regulations

Chapter 1	Health Canada Organization and Its History of Regulating Health Products in Canada.....	1
	<i>Updated by Hetal Mokashi, MBA and Penny Wilks, ND, RAC</i>	
Chapter 2	Good Laboratory Practice for Nonclinical Laboratory Studies	11
	<i>Updated by Navneet Sekhon</i>	
Chapter 3	Clinical Trial Applications, Good Clinical Practices.....	19
	<i>By Mahdis Dorkalam, MSc, RHN, and Navneet Sekhon</i>	
Chapter 4	Good Manufacturing Practices and Establishment Licensing in Canada	29
	<i>By Bocar Guisse, MSc and Fraidianie Sévigné</i>	
Chapter 5	New Drug Submission Process.....	45
	<i>Updated by Susanne Picard and Janice Weiler</i>	
Chapter 6	Postmarketing and Other Activities	59
	<i>Updated by Janice Weiler and Danny Germain, RAC</i>	

Chapter 7	Health Product Vigilance and Risk Management	69
	<i>Updated by Christopher Antonio, Roshni Celeste, Jenna Griffiths, Carole Légaré, Marc Poitras, Tanya Ramsamy, Thanh Vu, Bruce Wozny and Raymond Yang</i>	
Chapter 8	An Overview of Pharmaceutical Intellectual Property Protection in Canada.....	79
	<i>By Junyi Chen, JD, PhD, Danny Germain, RAC, Gordon Jepson, MA, LLB, and Bhavesh Patel, CChem</i>	
Chapter 9	Abbreviated New Drug Submissions.....	95
	<i>Updated by Bhavesh Patel, CChem, Bocar Guisse, MSc and Fraidiane Sevine</i>	
Chapter 10	Nonprescription Drugs	105
	<i>Updated by Kristin Willemsen</i>	
Chapter 11	Biologics Submission, Approval and Postmarketing.....	115
	<i>Updated by Marcia Sam and Mahdis Dorkalam, MSc, RHN</i>	
Chapter 12	Labelling, Advertising and Promotion: Prescription Pharmaceutical Drugs, Biologics and Radiopharmaceuticals	127
	<i>Updated by Marcia Sam, Veronica Yip and Sandra Alderdice</i>	
Chapter 13	electronic Common Technical Document (eCTD).....	133
	<i>By Khaled Yabiaoui, MSc, RAC</i>	
Chapter 14	Product Lifecycle Management Guidance.....	143
	<i>By Ajay Babu Pazhayattil, Naheed Sayeed-Desta and Queenia Lee</i>	
Index		149

Figures

Figure 1-1.	Health Canada.....	2
Figure 1-2.	Branches with Responsibility for the Regulation of Healthcare Products	3
Figure 5-1.	Diagram of the NDS Submission and Approval Procedure	51
Figure 5-2.	Example Boxed Text for Product Approved Under the NOC/c Policy	52
Figure 6-1.	Form IV Patent List	64
Figure 13-1.	Structure of a Regulatory Transaction in eCTD Format	135
Figure 13-2.	End-to-End Process for Preparing and Filing Regulatory Transactions in eCTD Format	141

Tables

Table 1-1.	Timeline—Regulating Health Products in Canada.....	6
Table 2-1.	Examples of Studies and the Requirement for GLP Compliance	14
Table 3-1.	Contents of a CTA Submission Package	22
Table 3-2.	Quality Changes—Biologics and Radiopharmaceuticals.....	24
Table 3-3.	Quality Changes—Pharmaceuticals	25
Table 3-4.	Postapproval Requirements.....	27
Table 4-1.	Definitions for Terms in This Chapter.....	30
Table 4-2.	GMP Regulations Applicable to Licensable Activities.....	33
Table 5-1.	Presentation of Information in the Common Technical Document (CTD) Format	49
Table 5-2.	Target Review Times	53
Table 7-1.	Clinical Trial Definitions	71
Table 7-2.	Postapproval Stage Definitions	74

Table 9-1.	Target Review Times	102
Table 10-1.	NAPRA Scheduling Factors.....	110
Table 11-1.	Drug Substance (Biologics and Radiopharmaceuticals).....	118
Table 11-2.	Drug Product (Biologics and Radiopharmaceuticals).....	119
Table 11-3.	Sample Table of Contents for a Schedule D (Biological) Product Monograph (PM)	120
Table 11-4.	Summary of Requirements for Evaluation Groups.....	123
Table 13-1.	Localization of Main XML Files Within an eCTD Sequence	136
Table 13-2.	Canadian eCTD Envelope Elements	136
Table 13-3.	m2-m5 eCTD Attributes	137
Table 13-4.	Validation Rule Samples and Their Descriptions and Severities	137
Table 13-5.	Document Formats Health Canada Expects for Specific Documents	138
Table 13-6.	Lifecycle Management Table Template	138
Table 13-7.	Lifecycle Management Table Example with Three Regulatory Activities and Related Regulatory Transactions.....	139
Table 13-8.	Lifecycle Management of Specific Documents.....	140

■ SECTION III: Fundamentals of EU Pharmaceutical and Biologics Regulations

See Volume 2 of *Fundamentals of Pharmaceutical and Biologics Regulations*

■ SECTION IV: Fundamentals of International Pharmaceutical and Biologics Regulations

See Volume 2 of *Fundamentals of Pharmaceutical and Biologics Regulations*

Table of Contents

■ SECTION I: Fundamentals of US Pharmaceutical and Biologics Regulations

See Volume 1 of *Fundamentals of Pharmaceutical and Biologics Regulations*

■ SECTION II: Fundamentals of Canadian Pharmaceutical and Biologics Regulations

See Volume 1 of *Fundamentals of Pharmaceutical and Biologics Regulations*

■ SECTION III: Fundamentals of EU Pharmaceutical and Biologics Regulations

Chapter 1	EMA and Other Regulatory Bodies.....	1
	<i>Updated by Ratinder Dhami, MSRA, RAC</i>	
Chapter 2	History of EU Regulations.....	13
	<i>Updated by Sabina Hoekstra-van den Bosch, PharmD, FRAPS</i>	
Chapter 3	Overview of Drug and Biologic Regulatory Pathways.....	31
	<i>Updated by Katbrin Schalper, PhD, RAC</i>	
Chapter 4	Preparing for EMA Meetings Prior to Submission of a Marketing Authorisation Application.....	41
	<i>Updated by Kell Cannon, Kate Dion and Cindy DiBiasi</i>	
Chapter 5	Preparing for EMA Meetings During Review of a Marketing Authorisation Application.....	53
	<i>By Kell Cannon, Kate Dion and Cindy DiBiasi</i>	
Chapter 6	EU Pricing and Reimbursement.....	61
	<i>Updated by Anu Gaur, PhD, MBA, MSRA, RAC</i>	
Chapter 7	Health Technology Assessment (HTA).....	77
	<i>Updated by Azzurra Ravizza, MSc and Monique Carter, MS, RAC</i>	
Chapter 8	The Paediatric Regulation.....	93
	<i>Updated by Karl-Heinz Huemer, PhD, MD</i>	

Chapter 9	Advertising and Promotion.....	103
	<i>Updated by Karen Zhou, JD, MS, RAC</i>	
Chapter 10	Enforcement and Competent Authorities	115
	<i>Updated by Sabina Hoekstra-van den Bosch, PharmD, FRAPS</i>	
Chapter 11	European Union Falsified Medicines Directive: Requirements and Implications for Multi-Stakeholder Healthcare Delivery	121
	<i>Updated by Yolanda García Barruso</i>	
Chapter 12	Regulatory Strategy	135
	<i>Updated by Karen Fan, MSc, PEng, RAC</i>	
Chapter 13	Overview of Authorisation Procedures for Medicinal Products	141
	<i>Updated by Sharry Arora, MPharm</i>	
Chapter 14	Adaptive and Alternative Pathways	159
	<i>Updated by Kathrin Schalper, PhD, RAC</i>	
Chapter 15	Preclinical Testing and Good Laboratory Practice Regulations.....	165
	<i>Updated by Anu Gaur, PhD, MBA, MSRA, RAC</i>	
Chapter 16	Medicinal Product Clinical Trials	173
	<i>Updated by Ashley Clark, MSc, RAC</i>	
Chapter 17	Registration Procedures for Medicinal Products.....	205
	<i>Updated by Jocelyn Jennings, MS, RAC</i>	
Chapter 18	Quality Systems and Inspectorate Process—Pharmaceuticals	227
	<i>Updated by Treena Jackson, MS, MA, CQA, CSSGB, RAC and Siegfried Schmitt, PhD</i>	
Chapter 19	Generic Medicinal Products	241
	<i>Updated by Nicole Beard MSc, PhD</i>	
Chapter 20	Biosimilar Medicinal Products.....	257
	<i>Updated by Jocelyn Jennings, MS, RAC</i>	
Chapter 21	Nonprescription Medicinal Products	267
	<i>Updated by Nicole Beard MSc, PhD</i>	
Chapter 22	Marketing Authorisations for Products Derived From Biotechnology.....	277
	<i>Updated by Jocelyn Jennings, MS, RAC</i>	
Chapter 23	Pharmaceutical Postauthorisation Requirements and Compliance With the Marketing Authorisation	287
	<i>Updated by Sharry Arora, MPharm</i>	
Chapter 24	Pharmacovigilance	301
	<i>Updated by Jocelyn Jennings, MS, RAC</i>	
Chapter 25	Regulatory Framework for Advanced Therapy Medicinal Products	315
	<i>By Daniela Drago, PhD, RAC, Florence Houn, MD, MPH and James McBlane, PhD</i>	

Chapter 26	Human Tissue Regulation	335
	<i>Updated by Nicole Beard, MSc, PhD</i>	
Chapter 27	Vaccines	353
	<i>Updated by Frédéric Béard</i>	
Chapter 28	Products Manufactured From Human Blood or Plasma	365
	<i>Updated by Nicole Beard, MSc, PhD</i>	
Chapter 29	Orphan Medicinal Products	375
	<i>Updated by Jocelyn Jennings, MS, RAC</i>	
Chapter 30	Combination Products.....	389
	<i>Updated by Claudia Ising, FRAPS, RAC</i>	
Glossary.....		399
Index.....		419
Figures		
Figure 1-1.	EMA Mission.....	3
Figure 1-2.	EMA Organisational Structure	9
Figure 5-1.	Approximate Representation of Key CHMP, CAT and PRAC Feedback and Meetings Based on Standard Assessment Review Timeline	55
Figure 5-2.	Example Timeline for CHMP Meeting Preparation	57
Figure 6-1.	Factors Influencing Medicinal Product Pricing	62
Figure 6-2.	Overview of ERP across Europe (2013)	64
Figure 6-3.	Summary of Economic Evaluation Methods.....	66
Figure 6-4.	Types of Cost Containment Policies Adopted by Member States.....	67
Figure 6-5.	German Pricing for Medicinal Products Under AMNOG	70
Figure 7-1.	Process Map for France	85
Figure 7-2.	Process Map for Germany	86
Figure 7-3.	Mean Length of Time From EMA Authorisation to HTA Decision for Oncology Products.....	88
Figure 8-1.	PIP Procedure.....	98
Figure 11-1.	Comparison of EU <i>FMD</i> and Other Countries' Falsified Medicines Legislation	123
Figure 11-2.	Routes in the Medicinal Product Supply Chain by Which Falsified Active Substances may Reach Patients	125
Figure 11-3.	An Example of the Common Logo Online Retailers of Medicines Must Display.....	128
Figure 11-4.	Flowchart Representing Product and Information Flow With Unique Product Identifiers and Accompanying Verification and Repository Systems.....	131
Figure 14-1.	Product Eligibility for Adaptive Pathways Approach (Source: EMA, 2016).....	161
Figure 16-1	Clinical Trial Legislative Improvements	176
Figure 16-2	Regulation (EU) 536/2014	177
Figure 16-3	Clinical Trial Authorization Procedure.....	190
Figure 16-4	Clinical Trial Application Scientific Assessment	191
Figure 16-5	Clinical Trial Application: Part II Assessment	192
Figure 16-6.	Serious Adverse Event Reporting.....	196
Figure 17-1.	Initial Marketing Authorisation Application Through the Centralised Procedure	219
Figure 17-2.	Initial Marketing Authorisation Application Through the Decentralised Procedure.....	220

Figure 17-3. Initial Marketing Authorisation Application Through National Procedure and Mutual Recognition Procedure.....	221
Figure 18-1. Drug Lifecycle Regulations	228
Figure 18-2. Assessors and Inspectors.....	229
Figure 18-3. EU Legal Instruments	230
Figure 18-4. Inspections as Part of the Drug Approval Process	231
Figure 20-1. Biosimilar Development	259
Figure 20-2. Stages of Development of a Biosimilar Medicine.....	260
Figure 20-3. Timeline for Development of a Biosimilar Medicine.....	261
Figure 20-4. Biosimilar Product Development and Marketing Approval	263
Figure 24-1. Pharmacovigilance System Master File	305
Figure 24-2. ICSR Expedited Submissions Requirements.....	309
Figure 24-3. Signal Management Lifecycle.....	311
Figure 25-1. Decision Tree for Potential Pathways and Expedited Evaluation Programs in the EU	318
Figure 25-2. Decision Tree for Classification of TEPs and CTMPs.....	322
Figure 25-3. Decision Tree for the Classification of GTMPs	323
Figure 27-1. General Principles of VAMF Certification.....	355
Figure 27-2. Procedure for Seasonal Influenza Vaccines in the EU (EMA/56793/2014).....	359
Figure 29-1. Simplified View of the Designation Criteria	378
Figure 29-2. EMA Orphan Drug Designation Guide.....	380

Tables

Table 3-1. Differences Between Conditional Marketing Authorisation and Marketing Authorisation Under Exceptional Circumstances.....	36
Table 4-1. Overview of the Key EMA Advice Meetings and Their Goals	43
Table 4-2. Overview of the Different Steps Required for Each Meeting	45
Table 4-3. Timeline for Key Meeting Steps	46
Table 5-1. EMA Scientific Committees: Roles.....	54
Table 6-1. Overview of Reference Pricing and Country Baskets in Europe	65
Table 7-1. HTA and Associated Organisations in Select EU Member States.....	82
Table 7-2. Comparison of HTA in Germany, France, UK, Italy and Spain	83
Table 7-3. Summary of Time From EMA Authorisation to HTA Decision and Outcome.....	87
Table 11-1. Definitions of Key Terms in This Chapter	124
Table 11-2. Worldwide Examples of SFFC Medicines From 2008 to Present.....	126
Table 11-3. Different Medicinal Product Supply Chain Stakeholder Requirements Under the <i>FMD</i>	127
Table 11-4. <i>FMD</i> Definitions of Active Substances and Excipients	128
Table 11-5. EU Initiatives Relevant to the <i>FMD</i>	129
Table 11-6. Status of Third Country Listing Requests	130
Table 12-1. Regulatory Key Questions During Development.....	137
Table 13-1. Standard Timetable for Evaluation of a Centralised Application.....	148
Table 13-2. Mutual Recognition Procedure Flowchart.....	151
Table 13-3. Decentralised Procedure Flowchart	154
Table 16-1. Summary of Selected Significant Changes Under Regulation (EU) No. 536/2014 (<i>ECTR</i>)	178
Table 16-2. Definitions of Selected <i>Clinical Trials Directive</i> and <i>ECTR</i> Terms.....	180
Table 16-3. General Contents of Applications to Ethics Committees and National Competent Authorities	185
Table 16-4. Contents of Clinical Trial Application Dossier per the <i>ECTR</i>	193

Table 16-5.	Contents of DSUR.....	198
Table 17-1.	EU Module 1 Contents	215
Table 17-2.	EU eCTD Envelope Information	216
Table 19-1.	Legal Basis of EU Applications from Directive 2001/83/EC	245
Table 20-1.	Data Package Required for a Marketing Authorisation Application to EMA	264
Table 21-1.	Some Common Health Conditions Treated Using Nonprescription Medication	269
Table 21-2.	Comparison of EU MAA Procedure Advantages and Risks for Nonprescription Medicines	270
Table 24-1.	Overview of Good Pharmacovigilance Practices	303
Table 24-2.	Periodic Benefit-Risk Evaluation Report (PBRER), Development Safety Update Report (DSUR) and Risk Management Plan (RMP) Interchangeable Modules.....	308
Table 25-1.	EU Pathways and Expedited Evaluation Programs That Might Apply to ATMPs.....	317
Table 25-2.	ATMPs That Have Been Granted a Marketing Authorisation in the EU	319
Table 25-3.	Recent Examples of CAT ATMP Classifications.....	321
Table 26-1.	Serological Donor Testing Requirements	339
Table 26-2.	Structure of the Single European Code.....	340
Table 26-3.	Qualifications and Responsibilities of the Responsible Person Under the EUTCD, Qualified Person for Human Medicinal Products and Responsible Person for Regulatory Compliance Under the <i>EU MDR</i>	343
Table 26-4.	Standard Timetable for Initial ATMP Marketing Authorisation Application Evaluation Under the Centralised Procedure.....	345
Table 26-5.	General Applicable Regulatory Framework for Medical Products Containing Human Tissue Intended for Human Clinical use and its Interconnection with Directive 2004/23/EC (<i>Tissues and Cells Directive</i>)	348
Table 28-1.	Medicinal Products Derived From Human Plasma and Their Indications	367

■ SECTION IV: Fundamentals of International Pharmaceutical and Biologics Regulations

Chapter 1:	Introduction to International Regulatory Affairs.....	1
	<i>Updated by Rowena Cook, MS, RAC and Sharad Mi Shukla, RAC</i>	
Chapter 2:	Crisis Management for the Healthcare Product Industry.....	11
	<i>Updated by Treena Jackson, MS, MA, CQA, RAC (US), CSSGB</i>	
Chapter 3:	Clinical Trials, Good Clinical Practice, Regulations, and Compliance	19
	<i>Updated by Anu Gaur, PhD, MBA, MSRA, RAC, Bettina Merz-Nideroest, MPharm, and Andrea Zobel, PhD</i>	
Chapter 4:	In-Country Representation	35
	<i>Updated by Pei-Ting S. Chou, PCQI, RAC</i>	
Chapter 5:	International Advertising and Promotion.....	55
	<i>Updated by Treena Jackson, MS, MA, CQA, RAC (US), CSSGB</i>	
Chapter 6:	Compliance and Enforcement.....	65
	<i>Updated by David W. Husman, PhD, ASQ CPGP, RAC and John Rossman, MBEE, RAC</i>	
Chapter 7:	International Counterfeit Regulations.....	87

Updated by Jos Kraus, PharmD, FRAPS and Siegfried Schmitt, PhD

Chapter 8:	Regulatory Reliance.....	113
	<i>By Daniela Drago, PhD, RAC and Murray M. Lumpkin, MD, MSc</i>	
Chapter 9:	Pricing and Reimbursement	123
	<i>Updated by Anu Gaur, PhD, MBA, MSRA, RAC</i>	
Chapter 10:	Health Technology Assessment (HTA).....	143
	<i>Updated by Azzurra Ravizza, MSc and Monique Carter, MS, RAC</i>	
Chapter 11:	Premarket Requirements/Dossier Requirements.....	177
	<i>Updated by Monique Carter, MS, RAC and Jesshanie Tabaniag</i>	
Chapter 12:	Authorization Procedures for Pharmaceutical Products	187
	<i>Updated by Orin Chisholm, GCULT, PhD, MTOPRA, SFHEA and Monique Carter, MS, RAC, MTOPRA</i>	
Chapter 13:	Stability Test Requirements	207
	<i>Updated by Sharry Arora, MPharm and Rosie Darwes</i>	
Chapter 14:	Quality Systems and Inspectorate Process for Pharmaceuticals.....	221
	<i>Updated by Siegfried Schmitt, PhD</i>	
Chapter 15:	Generic Drug Products.....	243
	<i>Updated by Pallavi Trivedi, MPH, RAC and Anu Gaur, PhD, MBA, MSRA, RAC</i>	
Chapter 16:	Over-the-Counter (OTC) Products.....	261
	<i>Updated by Robert Falcone, PhD</i>	
Chapter 17:	Pharmaceutical Postmarketing and Compliance.....	273
	<i>Updated by Kathrin Schalper, PhD, RAC</i>	
Chapter 18:	High-Risk Products: Products Derived from Biotechnology.....	289
	<i>Updated by Jocelyn Jennings, MS, RAC and Angela L. Nelson, MBA, RAC</i>	
Chapter 19:	Biosimilars: Basics and Recent Developments.....	309
	<i>Updated by Pallavi Trivedi, MPH, RAC</i>	
Chapter 20:	Vaccines	355
	<i>Updated by Nicole Beard, MSc, PhD</i>	
Chapter 21:	Products Manufactured from Human Blood and Plasma.....	375
	<i>Updated by Indraneel Dasari, RAC</i>	
Chapter 22:	Principles of Rare Diseases and Orphan Products Development	405
	<i>Updated by Todd J. Banks, PharmD, RPh, Ken Bonnell, MS, MBA, and Phu Bo Chung, JD, MS, RAC</i>	
Chapter 23:	Combination Products.....	421
	<i>Updated by Deanna Hughes, MS, RAC and Beat U. Steffen, MSc, MBA</i>	
Chapter 24:	Regulatory Considerations for Cell-Based Medicinal Products.....	439
	<i>By Indraneel Dasari, RAC</i>	

Chapter 25: Botanical Drug Products and Traditional Medicine.....	459
<i>Updated by Robert Falcone, PhD</i>	
Chapter 26: Global Pediatric Drug Development.....	481
<i>By Lynne Georgopoulos, RN, MSHS, RAC and Azzurra Ravizza, MSc</i>	
Abbreviations and Acronyms	513
Glossary of Terms.....	525
Index.....	533

Figures

Figure 3-1. Acceptance of Foreign Clinical Data	25
Figure 3-2. Quality Management System	30
Figure 6-1. TPLC Cycle for Devices	67
Figure 6-2. Medical Device Design Control and Review Process	71
Figure 7-1. WHO Global Monitoring System	106
Figure 8-1. Building Confidence and Trust for Greater Reliance.....	115
Figure 9-1. Factors Influencing Medicinal Product Pricing	124
Figure 9-2. Overview of ERP Across Europe (2013).....	127
Figure 9-3. Summary of Economic Evaluation Methods.....	129
Figure 9-4. Types of Cost Containment Policies Adopted by Member States.....	130
Figure 9-5. German Pricing for Medicinal Products Under AMNOG	134
Figure 10-1. Process Map for France	149
Figure 10-2. Process Map for Germany	151
Figure 10-3. Mean Length of Time From EMA Authorisation to HTA Decision for Oncology Products.....	152
Figure 10-4. Process Map for England.....	154
Figure 10-5. Process Map for Scotland	155
Figure 10-6. Historical MaHTAS Milestones	159
Figure 10-7. Flow Diagram of HTA in South Korea.....	162
Figure 10-8. Framework for Pricing Drugs and Devices in Japan.....	163
Figure 10-9. Map of Australian Government HTA Processes for Market Entry and Reimbursement Processes..	164
Figure 10-10. Timeline of US “HTA Like” Bodies.....	165
Figure 10-11. Overview of the Canada Public System Reimbursement Decision Pathway.....	169
Figure 10-12. HTA Timeline in Latin America	170
Figure 11-1. CTD Organization.....	180
Figure 14-1. Drug Lifecycle Regulations	222
Figure 14-2. Assessors and Inspectors.....	223
Figure 14-3. EU Legal Instruments	226
Figure 14-4. Inspections as Part of the Drug Approval Process	227
Figure 17-1. MedDRA Coding Hierarchy.....	282
Figure 19-1. Influence of Stakeholders as Drives of Biosimilars	313
Figure 19-2. Standalone vs. Abbreviated Development Programs	330
Figure 19-3. Regulation in Latin America	349

Figure 20-1. OCABR Decision Flowchart (Extracted from EU Administrative Procedure for Official Control Authority Batch Release—Human Vaccine and Blood Derived Medicinal Products)	363
Figure 20-2. Process of Influenza Vaccine Virus Selection and Development.....	365
Figure 20-3. Standard Evaluation Process Compared With Rolling Review of COVID-19 Vaccines	369
Figure 21-1. Convalescent Plasma Collection Workflow	381
Figure 21-2. Overview of Blood Product Manufacturing Process.....	382
Figure 21-3. Approaches to be Employed During Blood Product Processing	387
Figure 24-1. Cell Therapy Product Sources and ATMP Manufacturing Process Overview.....	441
Figure 24-2. Indications of Advanced Therapy Trials	442
Figure 24-3: Summary Schematic of DC Monocyte-Based Therapy for COVID-19 Treatment	445
Figure 24-4. ATMP Process Development Framework.....	445
Figure 24-5. Overview of ATMP Approval Centers in the US, EU, and Japan	448
Figure 24-6. Challenges Facing Industry and Regulators.....	457
Figure 25-1. US Regulatory Pathway for Marketing Botanical Products.....	466
Figure 25-2. Information Needed in a Botanical Drug Product IND.....	471
Figure 26-1. Overview of the iPSP Process.....	491
Figure 26-2. Phases in PIPs	496
Figure 26-3. Assessment Pathways for UK-PIPs	499
Figure 26-4. Assessment Pathways for UK-PIP Modifications	501

Tables

Table 3-1. Regional Regulatory Authorities	26
Table 6-1. Applicability of GxPs to Standardized Market Authorization Application Formats.....	75
Table 7-1. Definitions of Key Terms in This Chapter.....	89
Table 7-2. Methods to Reduce the Risk for Counterfeit and Falsification and Ensure Product Traceability	90
Table 7-3. DSCSA Definition of Stakeholders and Key Terminology	92
Table 7-4. FDA Timelines for Implementation of Key Plan Elements.....	93
Table 7-5. Different Medicinal Product Supply Chain Stakeholder Requirements Under the FMD	99
Table 7-6. Persons or Institutions That May Be Considered Exempt by Individual States.....	101
Table 7-7. Examples of Substandard and Falsified Products Reported to the GSMS (2013-2017)	105
Table 9-1. Overview of Reference Pricing and Country Baskets in Europe	128
Table 10-1. Summary of Time From EMA Authorisation to HTA Decision and Outcome.....	148
Table 10-2. HTA and Associated Organizations in Selected EU Member States and the UK.....	150
Table 10-3. Comparison of HTA in Germany, France, UK, Italy, and Spain.....	153
Table 10-4. Summary of HTA Status in Select Asian Countries	157
Table 10-5. MaHTAS 1995–2018 Impact Overview	158
Table 10-6. 13 Selected Products for Japan MHLW 3-Year HTA Pilot Evaluation	160
Table 10-7. Drugs Eligible for CADTH's Drug Review Processes	161
Table 10-8. Summary of CADTH's Elements and Recommendation Categories	166
Table 10-9. Latin American Country-Specific HTA Overview	167
Table 11-1. ACTD Format and Content	184
Table 12-1. ICH Members (as of May 2020)	188
Table 12-2. Country-Specific Regulatory Requirements.....	190
Table 13-1. Climatic Zones	208
Table 13-2. WHO Recommended Stability Testing Conditions for Drug Substance and Drug Product.....	212

Table 13-3.	Recommended Stability Storage Conditions for Refrigerated and Frozen Drug Substance and Drug Product.....	213
Table 13-4.	Country-Specific Climatic Zones and Stability Data Requirements for Asia Pacific Region	216
Table 13-5.	Country-Specific Climatic Zones and Stability Data Requirements for Latin America	217
Table 13-6.	Country-Specific Climatic Zones and Stability Data Requirements for SEE, Middle East, and Africa	218
Table 14-1.	PIC/S Member States	235
Table 15-1.	Comparative Study Parameter Assessment Between the US, EU, and Canada	245
Table 15-2.	GDUFA II User Fee Rates.....	248
Table 15-3.	Comparison of Generic Product Development Regulatory Requirements in Select Countries.....	249
Table 17-1.	MAH Reporting Requirements.....	283
Table 18-1.	Comparison of ICH CTD and ASEAN CTD Structures.....	302
Table 19-1.	Terminology Used in Regulatory Guidelines.....	311
Table 19-2.	WHO Written Procedures Providing Guidance on Evaluation of SBPs.....	314
Table 19-3.	Advantages and Disadvantages of Equivalence/Noninferiority Designs for SBPs	315
Table 19-4.	EMA Biosimilar Marketing Approvals via the Centralised Procedure.....	317
Table 19-5.	Biosimilars Recommended for Granting Upon Positive Opinion Adopted by CHPM	322
Table 19-6.	EU Guidelines for Biosimilars.....	323
Table 19-7.	Typical Biosimilar Product Marketing Application Dossiers and Data Requirement for Approval in the EU.....	325
Table 19-8.	Types of Formal FDA Meetings for Biosimilar Applications.....	329
Table 19-9.	Typical Dossier and Data Requirements for US Biosimilar Applications	333
Table 19-10.	PMDA-Approved Biosimilars as of November 2020.....	336
Table 19-11.	Typical Dossier and Data Requirements for Biosimilar Applications in Japan.....	338
Table 19-12.	Typical Application Dossier and Data Requirements for Biosimilar Marketing Applications	339
Table 19-13.	Similar Biologics Approved and Marketed in India	341
Table 19-14.	Typical Application Dossier and Data Requirement for Biosimilar Marketing Applications and Approvals in China.....	344
Table 19-15.	MFDS-Approved Biosimilars	345
Table 19-16.	Typical Application Dossier and Data Requirements for Biosimilar Marketing Applications and Approvals in Korea	346
Table 19-17.	Australia and New Zealand	348
Table 19-18.	Typical Application Dossier and Data Requirements for Biosimilar Marketing Applications and Approvals in Brazil	350
Table 21-1.	Overview of Products Manufactured From Blood and Their Clinical Significance	377
Table 21-2.	Overview of Blood Product Approvals Obtained in the US.....	379
Table 21-3.	Dosing of Convalescent Plasma During the Coronavirus Epidemic.....	383
Table 21-4.	Evidence of Infection Transmission by Human Blood	385
Table 21-5.	Potential Risks Identified for Manufacturing Process Steps	386
Table 22-1.	Global Themes Associated With Rare Disease Development Programs	407
Table 22-2.	FDA Expedited Programs for Serious Conditions	410
Table 22-3.	Overview of Orphan Drug Framework.....	411
Table 22-4.	EU and US Financial Implications of Orphan Drug Pricing and Reimbursement	412
Table 23-1.	Examples of FDA-Approved Combination Products.....	424
Table 23-2.	Combination Product Categories	425

Table 23-3.	Applicable Articles When the Medicinal Product is Ancillary.....	432
Table 23-4.	Applicable Articles for Devices to Administer Medicinal Products	434
Table 24-1.	Approved ATMPs in the US, EU, and Japan.....	443
Table 24-2.	Doses of Medical Products Comprising Human Cells, Genes, and Tissues	444
Table 24-3.	Summary of Risk Factors Associated with Transmission of COVID-19 During Manufacturing of ATMPs.....	446
Table 24-4.	Proposed Risk Classification for ATMPs with Respect to COVID-19	446
Table 24-5.	Overview of Applicable Regulatory Guidelines in the US, EU, and Japan.....	447
Table 24-6.	EU Regulatory Scenarios.....	449
Table 24-7.	US Regulatory Scenarios	451
Table 24-8.	Overview of Applicable US Regulatory Guidelines	452
Table 24-9.	Overview of Applicable EU Regulatory Guidelines	453
Table 24-10.	Overview of Applicable Regulatory Guidelines in Japan.....	455
Table 25-1.	Traditional Herbal or Botanical Product Regulations in Selected Countries.....	463
Table 25-2.	Direct-to-OTC Criteria for BDPs With Only Non-US Experience.....	469
Table 25-3.	Strategic Considerations for Developing a BDP for US Approval.....	472
Table 25-4.	Comparison of BDPs and Conventional Drugs	473
Table 26-1.	FDA Pediatric Age Categories for Labeling of Drugs and Biologics	486
Table 26-2.	Timeline of Key Pediatric Drug Development Initiatives, Guidances, and Legislative Actions Undertaken in the US.....	487
Table 26-3.	Overview of BPCA and PREA.....	489
Table 26-4.	Outline of the initial Pediatric Study Plan (iPSP).....	492
Table 26-5.	Timeline of Key Pediatric Initiatives Undertaken in the EU.....	493
Table 26-6.	Pediatric Regulation-Key Requirements and Incentives.....	494
Table 26-7.	Overview of Information Required in a PIP	498